DAX24.284 ±-0,0%Est505.744 -0,3%MSCI World4.343 -0,1%Top 10 Crypto11,55 -0,1%Nas23.429 +0,5%Bitcoin74.879 -0,5%Euro1,1779 +0,1%Öl62,04 ±-0,0%Gold4.487 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 DroneShield A2DMAA NVIDIA 918422 Tesla A1CX3T Bayer BAY001 Lufthansa 823212 Deutsche Telekom 555750 Siemens Energy ENER6Y TUI TUAG50 Allianz 840400 RENK RENK73 Novo Nordisk A3EU6F Deutsche Bank 514000 Amazon 906866 BASF BASF11
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich stabil -- Wall Street schließt höher -- Tesla-CEO Musk sichert sich Milliarden-Aktienpaket -- BYD, Nike, Siemens Energy, D-Wave, Lufthansa, Bayer, Rüstungsaktien, Gold, Bitcoin im Fokus
Top News
Plan12 - monatliche Ausschüttungen, die das Leben bereichern Plan12 - monatliche Ausschüttungen, die das Leben bereichern
Börsengehandelte Schuldverschreibungen: Wie ETNs funktionieren Börsengehandelte Schuldverschreibungen: Wie ETNs funktionieren
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

NeuroSense Therapeutics Aktie

Kaufen
Verkaufen
0,6300 EUR -0,0100 EUR -1,56 %
FSE
0,8500 USD +0,0560 USD +7,05 %
BTT
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.20,44 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3DFK1

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIL0011809592

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNRSN

NeuroSense Therapeutics Aktien News

DatumMeistgelesen
PR NewswireNeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
PR NewswireNeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024
PR NewswireNeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics
PR NewswireNeuroSense Announces Year End 2023 Financial Results and Provides Business Update
PR NewswireNeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial
PR NewswireNeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule
PR NewswireNeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts
PR NewswireNeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
PR NewswireNeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial
PR NewswireNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints
PR NewswireNeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023
PR NewswireNeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update
PR NewswireNeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness
PR NewswireNeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences
PR NewswireNeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023
PR NewswireNeuroSense Therapeutics to Participate in BIO-Europe Fall
PR NewswireNeuroSense CEO Provides Q3 2023 Update
PR NewswireNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model
PR NewswireEuropean Medicines Agency Grants NeuroSense SME Status
PR NewswireNeuroSense Granted Patents in Europe, Japan, and Israel for its ALS Drug PrimeC
PR NewswireNeuroSense to Participate in Upcoming ALS Conferences: PACTALS in Malaysia and NEALS in the U.S.
PR NewswireNeuroSense to Host Investor Webinar on September 12, 2023
PR NewswireNeuroSense Announces Second Quarter 2023 Financial Results and Provides Business Update
PR NewswireNeuroSense to Host Investor Event in Cambridge, Massachusetts on July 24, 2023
PR NewswireNeuroSense to Participate in Upcoming ALS Conferences: European Network to Cure ALS & EverythingALS Digital Biomarkers Summit
PR NewswireNeuroSense CEO Provides Q2 2023 Update
PR NewswireNeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement
PR NewswireNeuroSense Reports First Quarter 2023 Financial Results & Provides Business Update: Phase 2b ALS Trial Completes Enrollment, Topline Data Expected Q4 2023
PR NewswireNeuroSense Completes Enrollment in Phase 2b ALS Clinical Trial
PR NewswireNeuroSense Therapeutics Reports Positive Preliminary Results in Parkinson's Biomarker Study
PR NewswireNeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
PR NewswireNeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
PR NewswireNeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
PR NewswireNeuroSense Announces Year End 2022 Financial Results and Provides Business Update
PR NewswireNeuroSense Therapeutics to Participate in BIO-Europe Spring
PR NewswireNEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
PR NewswireNeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
PR NewswireNeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
PR NewswireNeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
PR NewswireNeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study

NeuroSense Therapeutics News

NeuroSense Therapeutics News: auf dieser Seite finden Sie alle NeuroSense Therapeutics News und Nachrichten zur NeuroSense Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch NeuroSense Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um NeuroSense Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.